Scott John K Jr.
Insider CIK 1753763 · NAVB Director, 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| NAVB NAVIDEA BIOPHARMACEUTICALS | J Other deriv | 2023-11-27 | 2023-12-05 | 64,289 | $100.00 | $6.43M | 64,289 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | J Other deriv | 2023-11-27 | 2023-12-05 | 2,400 | $1000.00 | $2.40M | 0 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | J Other | 2023-11-27 | 2023-12-05 | 2,270 | — | $0 | 0 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | A Award | 2023-06-29 | 2023-06-30 | 12,200,000 | $0.09 | $1.10M | 31,755,832 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | C Conversion deriv | 2023-06-05 | 2023-06-15 | 11,969 | $100.00 | $1.20M | 0 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | A Award | 2023-06-05 | 2023-06-15 | 11,508,672 | — | $0 | 19,555,832 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | P Buy deriv | 2023-06-01 | 2023-06-15 | 11,969 | $100.00 | $1.20M | 11,969 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | J Other | 2023-06-01 | 2023-06-15 | 990 | — | $0 | 2,270 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | A Award | 2022-11-30 | 2022-11-30 | 1,250 | — | $0 | 8,109,645 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | A Award | 2022-10-31 | 2022-11-01 | 2,500 | — | $0 | 8,108,395 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | A Award | 2022-09-30 | 2022-10-04 | 2,500 | — | $0 | 8,105,895 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | A Award | 2022-08-31 | 2022-09-01 | 2,500 | — | $0 | 8,103,395 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | P Buy deriv | 2022-08-30 | 2022-09-01 | 2,400 | — | $0 | 2,400 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | P Buy deriv | 2022-08-30 | 2022-09-01 | 2,400 | — | $0 | 2,400 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | S Sale deriv | 2022-08-30 | 2022-09-01 | 1,740 | $1379.31 | $2.40M | 0 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | A Award | 2022-07-31 | 2022-08-01 | 2,500 | — | $0 | 8,100,895 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | A Award | 2022-06-30 | 2022-07-05 | 2,500 | — | $0 | 8,098,395 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | A Award | 2022-05-31 | 2022-06-01 | 2,500 | — | $0 | 8,095,895 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | A Award | 2022-04-30 | 2022-05-03 | 2,500 | — | $0 | 8,093,395 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | S Sale deriv | 2022-04-10 | 2022-05-03 | 50,000 | $2.30 | $115.0K | 0 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | P Buy deriv | 2022-04-10 | 2022-05-03 | 1,740 | $0.80 | $1.4K | 1,740 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | P Buy | 2022-04-10 | 2022-05-03 | 3,260 | — | $0 | 3,260 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | A Award | 2022-03-31 | 2022-03-31 | 2,500 | — | $0 | 8,090,895 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | A Award | 2022-02-28 | 2022-03-01 | 2,500 | — | $0 | 8,088,395 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | A Award | 2022-01-31 | 2022-02-01 | 2,500 | — | $0 | 8,085,895 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | A Award | 2021-12-31 | 2022-01-04 | 2,500 | — | $0 | 8,083,395 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | A Award | 2021-11-30 | 2021-12-02 | 1,250 | — | $0 | 8,080,895 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | A Award | 2021-11-15 | 2021-12-02 | 30,000 | — | $0 | 8,077,162 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | A Award | 2021-11-15 | 2021-12-02 | 2,483 | — | $0 | 8,079,645 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | P Buy deriv | 2021-03-02 | 2021-03-04 | 50,000 | $100.00 | $5.00M | 50,000 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | P Buy | 2020-08-30 | 2020-09-02 | 5,000 | $5.00 | $25.0K | 8,047,162 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | P Buy | 2020-02-13 | 2020-02-19 | 2,373,529 | $0.85 | $2.02M | 8,042,162 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | P Buy | 2019-12-06 | 2019-12-11 | 555,555 | $0.90 | $500.0K | 5,668,633 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | P Buy | 2019-06-18 | 2019-06-21 | 4,000,000 | $0.75 | $3.00M | 5,113,078 | SEC↗ |
| NAVB NAVIDEA BIOPHARMACEUTICALS | P Buy | 2019-03-22 | 2019-03-25 | 357,143 | $0.14 | $50.0K | 22,261,565 | SEC↗ |